Parallel development of BRAF inhibitors for melanoma and lung cancer in adults, AND for BRAF‐mutated brain tumours and histiocytosis in childrenAgreed PIP for the combination of dabrafenib + trametinib for glioma with BRAF‐V600 mutations (1–18‐year‐old patients). Here, BRAF is linked to melanoma.